Winter Park, Florida–(Newsfile Corp. – May 5, 2026) – Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company based in Winter Park, Florida, dedicated to advancing regenerative therapies for chronic diseases, today announced that its pivotal clinical study on kidney disease has received Institutional Review Board (IRB) approval and has been successfully submitted to ClinicalTrials.gov.
Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/295970_ckdstudy.jpg
This milestone marks an important step in Adia Nutrition’s ongoing research into new approaches for studying kidney disease. The approved study will focus on evaluating the safety of the company’s proprietary AdiaVita stem cell-based approach, which uses stem cells and exosomes derived from umbilical cord blood, in people with moderate to advanced chronic kidney disease (CKD). In addition to safety, the study will track changes in commonly used kidney function and inflammation markers over time to better understand how patients respond during the study period.
“IRB approval and our submission to ClinicalTrials.gov are important milestones that confirm this study meets established ethical and regulatory standards,” said Larry Powalisz, CEO of Adia Nutrition. “Reaching this stage allows us to move forward with participant recruitment and begin the structured process of collecting clinical data. We’re enthusiastic about advancing this research and gaining a clearer scientific understanding of our stem cell and exosome-based approach in individuals with chronic kidney disease.”
Key details of the upcoming study include:
Target Population: Adults diagnosed with Stage 2-4 chronic kidney disease.Primary Objectives: Assess improvements in key kidney function markers, including eGFR, serum creatinine, and inflammatory biomarkers.Study Design: Randomized, controlled trial evaluating Adia’s proprietary AdiaVita stem cell and exosome therapy combined with glutathione against control arms/standard care.Expected Impact: Provide robust clinical data supporting the role of stem cell therapy in kidney disease management and regeneration.
Recruitment for the study is expected to commence immediately upon acceptance on ClinicalTrials.gov. Eligible participants and healthcare providers interested in the trial are encouraged to visit www.adiamed.com or monitor ClinicalTrials.gov for updates.
This advancement underscores Adia Nutrition’s commitment to rigorous, science-driven innovation in the regenerative medicine sector and its focus on addressing large unmet medical needs through cutting-edge stem cell interventions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295970
Source: Adia Nutrition Inc.